| |
|
|
|
|
|
|
|||
|
Blood, 15 February 2006, Vol. 107, No. 4, pp. 1265-1275. Prepublished online as a Blood First Edition Paper on October 27, 2005; DOI 10.1182/blood-2005-09-3621.
Submitted September 9, 2005
Cell and Molecular Biology Graduate Program, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA; Combined Degree Graduate Program, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA * Corresponding author; email: weissmi{at}email.chop.edu.
Embryonic stem (ES) cells exhibit the remarkable capacity to become virtually any differentiated tissue upon appropriate manipulation in culture, a property that has been beneficial for studies of hematopoiesis. Until recently, the majority of this work utilized murine ES cells for basic research to elucidate fundamental properties of blood cell development and establish methods to derive specific mature lineages. Now, the advent of human ES cells sets the stage for more applied pursuits to generate transplantable cells for treating blood disorders. Current efforts are directed toward adapting in vitro hematopoietic differentiation methods developed for murine ES cells to human lines, identifying the key interspecies differences in biological properties of ES cells and overcoming current obstacles to generating ES cell-derived hematopoietic stem cells that are competent to repopulate adult hosts. The ultimate medical goal is to create patient-specific and generic ES cell lines that can be expanded in vitro, genetically altered and differentiated into cell types that can be used to treat hematopoietic diseases.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||